Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of some unusual options trading on Wednesday. Stock investors acquired 1,002 put options on the company. This is an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Insider Buying and Selling at Maravai LifeSciences

In other Maravai LifeSciences news, Director Gregory T. Lucier acquired 51,472 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average cost of $3.70 per share, with a total value of $190,446.40. Following the completion of the purchase, the director directly owned 106,595 shares of the company’s stock, valued at $394,401.50. This represents a 93.38% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernd Brust bought 216,212 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $702,689.00. Following the transaction, the chief executive officer owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. The trade was a 86.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 566,771 shares of company stock worth $1,880,244. Corporate insiders own 2.11% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Hedge funds have recently modified their holdings of the business. First Eagle Investment Management LLC grew its stake in shares of Maravai LifeSciences by 299.0% in the fourth quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock worth $5,848,000 after purchasing an additional 1,348,405 shares during the last quarter. Brummer Multi Strategy AB bought a new position in Maravai LifeSciences during the 4th quarter worth $1,488,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maravai LifeSciences during the 4th quarter worth about $226,000. R Squared Ltd bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at about $51,000. Finally, M&T Bank Corp acquired a new stake in shares of Maravai LifeSciences in the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $3.27 on Thursday. The stock’s 50-day moving average is $3.59 and its 200-day moving average is $3.12. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $5.03. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74. The stock has a market cap of $836.17 million, a P/E ratio of -3.89 and a beta of 0.39.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The business had revenue of $41.63 million for the quarter, compared to analyst estimates of $49.02 million. Equities research analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRVI. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Wells Fargo & Company increased their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.25.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.